Lipid peroxidation products and changes in phospholipid composition induced by indobufen in diabetic platelets

Indobufen is an antiaggregatory drug which first of all inhibits platelet aggregation by interfering with cyclooxygenase enzymes in platelets. We have investigated the influence of indobufen (200 mg twice daily for 10 days) on platelet lipid peroxidation and phospholipid metabolism in diabetic patie...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis research 1995-09, Vol.79 (5), p.483-490
Main Authors: DMOSZYNSKA, A, WALTER-CRONECK, A, LEDWOZYW, A
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Case-Control Studies
diabetes
Diabetes Mellitus - blood
Diabetes Mellitus - drug therapy
Female
Humans
indobufen
Isoindoles
Lipid Peroxidation - drug effects
Male
Medical sciences
Middle Aged
peroxidation
Pharmacology. Drug treatments
Phenylbutyrates - therapeutic use
phospholipids
Phospholipids - blood
Platelet Aggregation Inhibitors - therapeutic use
platelets
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Indobufen is an antiaggregatory drug which first of all inhibits platelet aggregation by interfering with cyclooxygenase enzymes in platelets. We have investigated the influence of indobufen (200 mg twice daily for 10 days) on platelet lipid peroxidation and phospholipid metabolism in diabetic patients. The production of lipid peroxidation products was significantly lower after drug treatment. Indobufen administration, however, had no influence on the fatty acid composition of platelet phospholipids.
ISSN:0049-3848
1879-2472
DOI:10.1016/0049-3848(95)00138-H